Insider Selling: Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Sells 17,500 Shares of Stock

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $43.07, for a total value of $753,725.00. Following the completion of the sale, the chief executive officer now directly owns 85,942 shares of the company's stock, valued at $3,701,521.94. This trade represents a 16.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Marshall Fordyce also recently made the following trade(s):

• On Wednesday, December 11th, Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock. The shares were sold at an average price of $46.94, for a total transaction of $821,450.00.
• On Wednesday, October 23rd, Marshall Fordyce sold 19,375 shares of Vera Therapeutics stock. The stock was sold at an average price of $40.39, for a total transaction of $782,556.25.
• On Wednesday, October 9th, Marshall Fordyce sold 15,625 shares of Vera Therapeutics stock. The shares were sold at an average price of $38.24, for a total transaction of $597,500.00.
• On Wednesday, September 25th, Marshall Fordyce sold 23,125 shares of Vera Therapeutics stock. The stock was sold at an average price of $46.05, for a total transaction of $1,064,906.25.

Vera Therapeutics Stock Up 1.3 %

VERA traded up $0.55 during trading on Friday, reaching $42.60. The company had a trading volume of 2,228,091 shares, compared to its average volume of 876,029. The company has a market cap of $2.70 billion, a P/E ratio of -16.32 and a beta of 1.08. Vera Therapeutics, Inc. has a 12 month low of $14.20 and a 12 month high of $51.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. The business's fifty day moving average price is $45.27 and its 200 day moving average price is $40.49.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.21). Equities analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Institutional Trading of Vera Therapeutics

A number of institutional investors have recently modified their holdings of the company. EFG Asset Management North America Corp. raised its position in Vera Therapeutics by 204.0% in the 2nd quarter. EFG Asset Management North America Corp. now owns 31,444 shares of the company's stock valued at $1,137,000 after buying an additional 21,101 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Vera Therapeutics by 6.3% in the second quarter. Bank of New York Mellon Corp now owns 165,322 shares of the company's stock valued at $5,981,000 after purchasing an additional 9,854 shares during the last quarter. Legato Capital Management LLC bought a new stake in shares of Vera Therapeutics in the second quarter worth $273,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Vera Therapeutics by 30.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,527 shares of the company's stock worth $272,000 after purchasing an additional 1,737 shares during the last quarter. Finally, TD Asset Management Inc grew its position in Vera Therapeutics by 18.4% in the second quarter. TD Asset Management Inc now owns 154,338 shares of the company's stock valued at $5,584,000 after purchasing an additional 24,000 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

VERA has been the topic of several recent research reports. Wedbush raised their price target on Vera Therapeutics from $30.00 to $38.00 and gave the stock a "neutral" rating in a research report on Friday, November 8th. Evercore ISI upgraded Vera Therapeutics to a "strong-buy" rating in a report on Monday, September 16th. JPMorgan Chase & Co. boosted their target price on Vera Therapeutics from $72.00 to $75.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. Guggenheim increased their price target on shares of Vera Therapeutics from $56.00 to $64.00 and gave the company a "buy" rating in a research report on Monday, October 28th. Finally, Scotiabank began coverage on shares of Vera Therapeutics in a report on Wednesday, October 16th. They set a "sector outperform" rating and a $60.00 price objective for the company. One analyst has rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Vera Therapeutics has a consensus rating of "Buy" and a consensus target price of $59.22.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.